| scholarly article | Q13442814 |
| P50 | author | Filip Janku | Q73569186 |
| P2093 | author name string | Jiri Polivka | |
| Martin Pesta | |||
| P2860 | cites work | Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer | Q24604601 |
| Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients | Q57240090 | ||
| Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer | Q58813330 | ||
| Molecular diagnostics and personalized medicine in oncology: Challenges and opportunities | Q59210186 | ||
| The use of fluorometric assays to assess the immune response to DNA in murine systemic lupus erythematosus | Q73489250 | ||
| Analysis of circulating tumor DNA in plasma at diagnosis and during follow-up of lung cancer patients | Q74020294 | ||
| K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance | Q74611864 | ||
| Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients | Q77804773 | ||
| Tumor DNA in plasma at diagnosis of breast cancer patients is a valuable predictor of disease-free survival | Q78632811 | ||
| Prognostic value of circulating KRAS2 gene mutations in colorectal cancer with distant metastases | Q79440192 | ||
| Free circulating DNA as possible tumour marker in colorectal cancer | Q79907708 | ||
| Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival | Q79954604 | ||
| Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer | Q81186156 | ||
| Detection and monitoring of cell-free DNA in blood of patients with colorectal cancer | Q82218655 | ||
| The value of serial plasma nuclear and mitochondrial DNA levels in patients with acute ischemic stroke | Q82734214 | ||
| Prognostic role of methylated free circulating DNA in colorectal cancer | Q83506585 | ||
| The value of serial plasma nuclear and mitochondrial DNA levels in acute spontaneous intra-cerebral haemorrhage | Q84239377 | ||
| Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas | Q85049473 | ||
| Assessment of SOX17 DNA methylation in cell free DNA from patients with operable gastric cancer. Association with prognostic variables and survival | Q86102397 | ||
| Loss of heterozygosity at tumor suppressor genes detectable on fractionated circulating cell-free tumor DNA as indicator of breast cancer progression | Q87382252 | ||
| The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP | Q24649549 | ||
| Liquid biopsies: genotyping circulating tumor DNA | Q27010159 | ||
| Evolution of the cancer genome | Q27020991 | ||
| Acquired resistance to EGFR-targeted therapies in colorectal cancer | Q27022741 | ||
| Targeting RAF kinases for cancer therapy: BRAF-mutated melanoma and beyond | Q27026323 | ||
| EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. | Q27851590 | ||
| Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing | Q27860948 | ||
| Circulating mutant DNA to assess tumor dynamics | Q28289337 | ||
| The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers | Q29395525 | ||
| Analysis of circulating tumor DNA to monitor metastatic breast cancer | Q29614797 | ||
| Detection of circulating tumor DNA in early- and late-stage human malignancies | Q29615778 | ||
| Tumor metastasis: molecular insights and evolving paradigms | Q29615908 | ||
| Circulating tumor cells, disease progression, and survival in metastatic breast cancer | Q29619276 | ||
| Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA | Q29620083 | ||
| Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer | Q30080026 | ||
| The origin of elevated levels of circulating DNA in blood plasma of premature neonates | Q33374139 | ||
| Analysis of cancer mutation signatures in blood by a novel ultra-sensitive assay: monitoring of therapy or recurrence in non-metastatic breast cancer | Q33507538 | ||
| An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. | Q33590850 | ||
| Detection of cancer DNA in plasma of patients with early-stage breast cancer. | Q33624889 | ||
| Plasma cell-free DNA in ovarian cancer: an independent prognostic biomarker | Q33790229 | ||
| BRAF V600E mutations in urine and plasma cell-free DNA from patients with Erdheim-Chester disease | Q33976971 | ||
| High fragmentation characterizes tumour-derived circulating DNA. | Q34016528 | ||
| Identification of double-stranded genomic DNA spanning all chromosomes with mutated KRAS and p53 DNA in the serum exosomes of patients with pancreatic cancer | Q34039531 | ||
| Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. | Q34116750 | ||
| Origin and quantification of circulating DNA in mice with human colorectal cancer xenografts | Q34117027 | ||
| Detection and quantification of mutations in the plasma of patients with colorectal tumors | Q34132363 | ||
| Cell-free nucleic acids as biomarkers in cancer patients | Q34184393 | ||
| Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. | Q34278191 | ||
| The prognostic value of KRAS mutated plasma DNA in advanced non-small cell lung cancer. | Q34317490 | ||
| Liquid biopsy: monitoring cancer-genetics in the blood | Q34356149 | ||
| LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival | Q34360216 | ||
| Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status | Q34473831 | ||
| Quantification and dynamic monitoring of EGFR T790M in plasma cell-free DNA by digital PCR for prognosis of EGFR-TKI treatment in advanced NSCLC. | Q34535332 | ||
| Multiple marker detection in peripheral blood for NSCLC diagnosis | Q34612077 | ||
| Clinical utility of a blood-based BRAF(V600E) mutation assay in melanoma | Q34646769 | ||
| Optimizing blood collection, transport and storage conditions for cell free DNA increases access to prenatal testing | Q34706270 | ||
| ??? | Q94720111 | ||
| Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer | Q34790678 | ||
| A novel blood collection device stabilizes cell-free RNA in blood during sample shipping and storage | Q34997703 | ||
| Degradation of chromosomal DNA during apoptosis | Q35091420 | ||
| Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA. | Q35127938 | ||
| Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment | Q35218647 | ||
| Tumor clone dynamics in lethal prostate cancer | Q35575930 | ||
| Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies | Q35828697 | ||
| Cell-free DNA in blood is a potential diagnostic biomarker of breast cancer | Q35995351 | ||
| Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood | Q36497457 | ||
| Aberrant DNA methylation of the p16INK4a gene in plasma DNA of breast cancer patients | Q36618056 | ||
| Circulating nucleic acids (CNAs) and cancer--a survey | Q36669780 | ||
| Tumor-associated copy number changes in the circulation of patients with prostate cancer identified through whole-genome sequencing. | Q36998629 | ||
| Comparison of circulating plasma DNA levels between lung cancer patients and healthy controls | Q37164447 | ||
| Utility of circulating B-RAF DNA mutation in serum for monitoring melanoma patients receiving biochemotherapy | Q37286893 | ||
| Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. | Q37646889 | ||
| Fine-needle aspiration (FNA) biopsy: historical aspects. | Q37649009 | ||
| Transformation of non-tumor host cells during tumor progression: theories and evidence | Q38003168 | ||
| Biological role of cell-free nucleic acids in cancer: the theory of genometastasis | Q38067163 | ||
| Circulating cell free DNA: Preanalytical considerations | Q38111116 | ||
| Non-invasive prenatal testing for aneuploidy: current status and future prospects | Q38114375 | ||
| Diagnostic and prognostic value of circulating tumor-related DNA in cancer patients. | Q38152782 | ||
| Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia | Q38153173 | ||
| The evolution of the unstable cancer genome | Q38198432 | ||
| Mechanism-based cancer therapy: resistance to therapy, therapy for resistance | Q38255064 | ||
| Circulating tumor cells and circulating tumor DNA for precision medicine: dream or reality? | Q38261856 | ||
| Analytical validation of BRAF mutation testing from circulating free DNA using the amplification refractory mutation testing system | Q38392527 | ||
| Detection of PIK3CA mutations in circulating free DNA in patients with breast cancer | Q38418038 | ||
| Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients | Q39877158 | ||
| Circulating plasma DNA as diagnostic biomarker in non-small cell lung cancer | Q40044848 | ||
| Prospective blinded study of BRAFV600E mutation detection in cell-free DNA of patients with systemic histiocytic disorders | Q40229747 | ||
| Brain tumor mutations detected in cerebral spinal fluid | Q40251034 | ||
| Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas. | Q41431886 | ||
| Cell-free nucleic acids circulating in the plasma of colorectal cancer patients induce the oncogenic transformation of susceptible cultured cells | Q42830431 | ||
| Potential clinical significance of a plasma-based KRAS mutation analysis in patients with advanced non-small cell lung cancer. | Q43166831 | ||
| DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells. | Q43540280 | ||
| A rapid direct fluorescent assay for cell-free DNA quantification in biological fluids. | Q43619042 | ||
| Real-time polymerase chain reaction quantification of free DNA in serum of patients with polyps and colorectal cancers | Q44508931 | ||
| Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing | Q44576396 | ||
| Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer | Q44670943 | ||
| Allelic imbalance on 12q22-23 in serum circulating DNA of melanoma patients predicts disease outcome | Q44829269 | ||
| Free circulating tumor DNA as a diagnostic marker for breast cancer. | Q46790581 | ||
| Effect of DNA size and strandedness on the in vivo clearance and organ localization of DNA. | Q47240807 | ||
| Dynamic plasma EGFR mutation status as a predictor of EGFR-TKI efficacy in patients with EGFR-mutant lung adenocarcinoma. | Q48151275 | ||
| Role of early cell-free DNA levels decrease as a predictive marker of fatal outcome after severe traumatic brain injury | Q48405515 | ||
| Evaluation of fluorescence-based methods for total vs. amplifiable DNA quantification in plasma of lung cancer patients. | Q50601729 | ||
| Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. | Q50882453 | ||
| Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma. | Q50889518 | ||
| The inverted pyramid of biomarker-driven trials. | Q51689988 | ||
| Prognostic significance of methylated RASSF1A and PITX2 genes in blood- and bone marrow plasma of breast cancer patients. | Q51733621 | ||
| Detection of TFPI2 methylation in the serum of hepatocellular carcinoma patients. | Q53262777 | ||
| Clinical significance of promoter hypermethylation of DNA repair genes in tumor and serum DNA in invasive ductal breast carcinoma patients. | Q54428093 | ||
| Prognostic value of circulating mutant DNA in unresectable metastatic colorectal cancer. | Q54450340 | ||
| Circulating hTERT DNA in early breast cancer. | Q54473567 | ||
| Methylated DNA and total DNA in serum detected by one-step methylation-specific PCR is predictive of poor prognosis for breast cancer patients. | Q54484988 | ||
| Levels of circulating cell-free nuclear and mitochondrial DNA in benign and malignant ovarian tumors. | Q54513784 | ||
| Quantification of free circulating tumor DNA as a diagnostic marker for breast cancer. | Q54520660 | ||
| Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan. | Q54537674 | ||
| A sensitive method to quantify human cell-free circulating DNA in blood: relevance to myocardial infarction screening. | Q54577373 | ||
| Molecular detection of APC, K- ras, and p53 mutations in the serum of colorectal cancer patients as circulating biomarkers. | Q54714698 | ||
| Increased plasma DNA integrity in cancer patients. | Q54763921 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biopsy | Q179991 |
| P304 | page(s) | 1631-1644 | |
| P577 | publication date | 2015-11-11 | |
| P1433 | published in | Expert Review of Molecular Diagnostics: new diagnostic technologies are set to revolutionise healthcare | Q15756305 |
| P1476 | title | Testing for oncogenic molecular aberrations in cell-free DNA-based liquid biopsies in the clinic: are we there yet? | |
| P478 | volume | 15 |
| Q52724596 | Analysis of circulating tumor DNA in breast cancer as a diagnostic and prognostic biomarker. |
| Q49710514 | Biomarker potential of ST6GALNAC3 and ZNF660 promoter hypermethylation in prostate cancer tissue and liquid biopsies |
| Q36238197 | Cell-Free DNA Provides a Good Representation of the Tumor Genome Despite Its Biased Fragmentation Patterns |
| Q26744505 | Current status of biomarker research in neurology |
| Q33568113 | Detection of Histone H3 mutations in cerebrospinal fluid-derived tumor DNA from children with diffuse midline glioma |
| Q42291714 | Detection of copy number alterations in cell-free tumor DNA from plasma |
| Q36378903 | Development and validation of an ultra-deep next-generation sequencing assay for testing of plasma cell-free DNA from patients with advanced cancer |
| Q90682389 | Epigenetic Biomarkers in the Management of Ovarian Cancer: Current Prospectives |
| Q64096563 | Liquid Biopsies Using Plasma Exosomal Nucleic Acids |
| Q48527971 | Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers |
| Q54950354 | Mechanisms and Therapy for Cancer Metastasis to the Brain. |
| Q38376723 | Multiplex KRASG12/G13 mutation testing of unamplified cell-free DNA from the plasma of patients with advanced cancers using droplet digital polymerase chain reaction |
| Q38376337 | Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers |
| Q38616628 | Mystery of the brain metastatic disease in breast cancer patients: improved patient stratification, disease prediction and targeted prevention on the horizon? |
| Q47801313 | Prognostic Significance of Circulating RET M918T Mutated Tumor DNA in Patients With Advanced Medullary Thyroid Carcinoma |
| Q91876298 | RAS/RAF mutations in tumor samples and cell-free DNA from plasma and bone marrow aspirates in multiple myeloma patients |
| Q45956385 | Saliva-Exosomics in Cancer: Molecular Characterization of Cancer-Derived Exosomes in Saliva. |
| Q64120390 | Salivary Exosomes as Nanocarriers for Cancer Biomarker Delivery |
| Q88319624 | Targeted methylation sequencing of plasma cell-free DNA for cancer detection and classification |
| Q92514391 | The Labyrinth of Product Development and Regulatory Approvals in Liquid Biopsy Diagnostics |
| Q54998576 | The Role of Circulating Free DNA and MicroRNA in Non-Invasive Diagnosis of HBV- and HCV-Related Hepatocellular Carcinoma. |
| Q89823370 | Using gold nanoparticles to detect single-nucleotide polymorphisms: toward liquid biopsy |
Search more.